Eravacycline - Tetraphase Pharmaceuticals

Drug Profile

Eravacycline - Tetraphase Pharmaceuticals

Alternative Names: TP-434; XERAVA

Latest Information Update: 16 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tetraphase Pharmaceuticals
  • Class Acetamides; Antibacterials; Pyrrolidines; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Intra-abdominal infections
  • No development reported Respiratory tract infections
  • Discontinued Urinary tract infections

Most Recent Events

  • 11 Oct 2018 Launched for Intra-abdominal infections in USA (IV) - First global launch
  • 04 Oct 2018 Tetraphase Pharmaceuticals plans a phase I trial for Bacterial infections (In children, In adolescents) in USA (IV) (NCT03696550)
  • 20 Sep 2018 Tetraphase Pharmaceuticals announces intention to launch eravacycline for complicated intra-abdominal infections in Europe in early 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top